| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Director | Common Shares | 1.73M | $90M | $52.03 | Jul 16, 2025 | Indirect |
| Nkarta, Inc. | Director | Stock Option (right to buy) | 46K | Jun 5, 2025 | Direct | ||
| Design Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (right to buy) | 19K | Jun 10, 2025 | Direct | ||
| CRISPR Therapeutics AG | Director | Stock Option (Right to Buy) | 13K | Jun 5, 2025 | Direct | ||
| Turning Point Therapeutics, Inc. | Director | Common Stock | 0 | $76.00 | Aug 17, 2022 | Indirect | |
| Turning Point Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | Aug 17, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | Jul 16, 2025 | 3 | $51.5M | 4 | Jul 17, 2025 | Director |
| DSGN | Design Therapeutics, Inc. | Jun 10, 2025 | 1 | $0 | 4 | Jun 12, 2025 | Director, 10%+ Owner |
| NKTX | Nkarta, Inc. | Jun 5, 2025 | 1 | $0 | 4 | Jun 9, 2025 | Director |
| CRSP | CRISPR Therapeutics AG | Jun 5, 2025 | 1 | $0 | 4 | Jun 6, 2025 | Director |
| DSGN | Design Therapeutics, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 17, 2024 | Director, 10%+ Owner |
| NKTX | Nkarta, Inc. | Jun 13, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
| CRSP | CRISPR Therapeutics AG | May 30, 2024 | 1 | $0 | 4 | May 31, 2024 | Director |
| NKTX | Nkarta, Inc. | Mar 27, 2024 | 2 | $20M | 4 | Mar 28, 2024 | Director |
| CRSP | CRISPR Therapeutics AG | Feb 27, 2024 | 3 | $75M | 4 | Feb 27, 2024 | Director |
| CRSP | CRISPR Therapeutics AG | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
| NKTX | Nkarta, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
| DSGN | Design Therapeutics, Inc. | May 31, 2023 | 1 | $0 | 4 | Jun 2, 2023 | Director, 10%+ Owner |
| DSGN | Design Therapeutics, Inc. | Dec 16, 2022 | 3 | $7.57M | 4 | Dec 20, 2022 | Director, 10%+ Owner |
| TPTX | Turning Point Therapeutics, Inc. | Aug 17, 2022 | 4 | -$171M | 4 | Aug 17, 2022 | Director |
| DSGN | Design Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director, 10%+ Owner |
| CRSP | CRISPR Therapeutics AG | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
| NKTX | Nkarta, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
| NKTX | Nkarta, Inc. | Apr 28, 2022 | 2 | $20M | 4 | Apr 29, 2022 | Director |
| NKTX | Nkarta, Inc. | Jun 13, 2021 | 1 | $0 | 4 | Jun 15, 2021 | Director |
| CRSP | CRISPR Therapeutics AG | Jun 10, 2021 | 1 | $0 | 4 | Jun 14, 2021 | Director |
| TPTX | Turning Point Therapeutics, Inc. | Jun 2, 2021 | 1 | $0 | 4 | Jun 4, 2021 | Director |